Loraine V. Upham
Founder at Cure DM, Inc.
Profile
Loraine V.
Upham is the founder of Cure DM, Inc., a company founded in 2004.
She currently holds the title of President, Chief Executive Officer & Director at Cure DM, Inc. Ms. Upham's former job positions include being a Member-Molecular Genetics Research Department at Eli Lilly & Co., a Principal at Merck & Co., Inc., a Product Manager & Project Team Leader at Packard BioScience Co., and a Manager-Business Development at Prolexys Pharmaceuticals, Inc. She also served as the Chief Operating Officer at Boston Therapeutics, Inc. in 2018.
Ms. Upham's education history includes an undergraduate degree from the University of Pennsylvania in 1982 and an MBA from Arizona State University in 1988.
Loraine V. Upham active positions
Companies | Position | Start |
---|---|---|
Cure DM, Inc.
Cure DM, Inc. BiotechnologyHealth Technology Cure DM, Inc. operates as a biopharmaceutical company. It develops new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin. The company was founded by Loraine V. Upham, Claresa S. Levetan and Rita El-Hajj in 2004 and is headquartered in Wilmington, DE. | Founder | 01/01/2004 |
Former positions of Loraine V. Upham
Companies | Position | End |
---|---|---|
NANOMIX CORPORATION | Chief Operating Officer | 30/11/2018 |
MERCK & CO., INC. | Corporate Officer/Principal | - |
Packard BioScience Co.
Packard BioScience Co. Medical SpecialtiesHealth Technology On July 13, 2001, the company entered into a merger agreement with PerkinElmer, Inc. Pursuant to the merger agreement, the company will become a subsidiary of PerkinElmer and each outstanding share of the company's common stock will be converted into 0.311 of a share of PerkinElmer common stock | Corporate Officer/Principal | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Corporate Officer/Principal | - |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Training of Loraine V. Upham
University of Pennsylvania | Undergraduate Degree |
Arizona State University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
MERCK & CO., INC. | Health Technology |
Private companies | 4 |
---|---|
Cure DM, Inc.
Cure DM, Inc. BiotechnologyHealth Technology Cure DM, Inc. operates as a biopharmaceutical company. It develops new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin. The company was founded by Loraine V. Upham, Claresa S. Levetan and Rita El-Hajj in 2004 and is headquartered in Wilmington, DE. | Health Technology |
Packard BioScience Co.
Packard BioScience Co. Medical SpecialtiesHealth Technology On July 13, 2001, the company entered into a merger agreement with PerkinElmer, Inc. Pursuant to the merger agreement, the company will become a subsidiary of PerkinElmer and each outstanding share of the company's common stock will be converted into 0.311 of a share of PerkinElmer common stock | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Boston Therapeutics, Inc.
Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
- Stock Market
- Insiders
- Loraine V. Upham